Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3625 | Simulation Intervention Wiki | 1.00 |
| drug1030 | Control Wiki | 0.28 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018288 | Carcinoma, Small Cell NIH | 1.00 |
| D055752 | Small Cell Lung Carcinoma NIH | 0.71 |
| D018358 | Neuroendocrine Tumors NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030357 | Small cell lung carcinoma HPO | 0.71 |
| HP:0100634 | Neuroendocrine neoplasm HPO | 0.58 |
| HP:0012125 | Prostate cancer HPO | 0.45 |
Navigate: Correlations HPO
There is one clinical trial.
An open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with mCRPC enrolled in Stage 2, with either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients will be treated with BXCL701 combined with PEMBRO.
Description: Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL12; and a greater than 50% prostate-specific antigen (PSA) decline from baseline.
Measure: Estimate the composite response rate of the combination of BXCL701 + PEMBRO Time: up to 36 monthsDescription: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.
Measure: Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and B Time: up to 36 monthsDescription: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro
Measure: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: The median time frame with overall survival with the use of BXCL701 in combination with Pembro
Measure: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: The timeframe in which the tumor reacts to BXCL701 in combination with Pembro
Measure: Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro
Measure: Determine the risk profile of the use of BXCL701 in combination with PEMBRO. Time: up to 36 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports